Website www.micreos.com Founded 2005 | Number of employees 50-200 Founder Mark Offerhaus | |
 | ||
Products ListexSalmonelexStaphefekt Products | ||
Micreos biotechnology wageningen
Micreos is a Netherlands-based phage- and endolysin technology development company. The company is the developer of Staphefekt, an endolysin that selectively kills Staphylococcus aureus bacteria. The substance is an ingredient in the firm's skincare brand Gladskin which targets inflammatory skin conditions.
Contents
Micreos has developed phage- and endolysin-based products against specific bacteria such as Listeria, Salmonella and MRSA. Listex is their antimicrobial processing aid used to prevent Listeria in food products including meat, fish and cheese. The USDA, Health Canada, and FSANZ have approved these uses. Salmonelex, aimed at prevention of cross contamination and the killing of undesirable Salmonella bacteria on food during processing - has been approved as a GRAS processing aid by the FDA. Mark Offerhaus serves as the company’s CEO.